StockNews.com Begins Coverage on Fresenius Medical Care (NYSE:FMS)

Equities research analysts at StockNews.com started coverage on shares of Fresenius Medical Care (NYSE:FMSGet Free Report) in a report issued on Friday. The brokerage set a “strong-buy” rating on the stock.

A number of other equities research analysts have also recently commented on the stock. Berenberg Bank started coverage on shares of Fresenius Medical Care in a report on Wednesday, November 6th. They set a “buy” rating and a $25.60 price target on the stock. Truist Financial increased their target price on Fresenius Medical Care from $22.00 to $23.00 and gave the company a “hold” rating in a research note on Monday, October 7th. Finally, Bank of America raised Fresenius Medical Care from an “underperform” rating to a “neutral” rating in a report on Monday, December 2nd. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, one has issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $24.30.

Read Our Latest Analysis on FMS

Fresenius Medical Care Stock Performance

Shares of Fresenius Medical Care stock opened at $22.15 on Friday. The stock has a market cap of $13.00 billion, a price-to-earnings ratio of 18.31, a PEG ratio of 0.96 and a beta of 0.93. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.37 and a quick ratio of 1.02. Fresenius Medical Care has a 1 year low of $17.93 and a 1 year high of $24.31. The firm’s 50-day moving average is $22.21 and its 200 day moving average is $20.64.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the stock. Allworth Financial LP grew its position in Fresenius Medical Care by 53.1% in the 3rd quarter. Allworth Financial LP now owns 1,675 shares of the company’s stock worth $36,000 after purchasing an additional 581 shares during the period. Wilmington Savings Fund Society FSB bought a new stake in shares of Fresenius Medical Care in the third quarter worth $38,000. GAMMA Investing LLC increased its position in Fresenius Medical Care by 50.4% during the third quarter. GAMMA Investing LLC now owns 4,998 shares of the company’s stock valued at $106,000 after acquiring an additional 1,675 shares during the last quarter. ORG Wealth Partners LLC bought a new position in Fresenius Medical Care in the third quarter valued at about $112,000. Finally, Venturi Wealth Management LLC boosted its position in Fresenius Medical Care by 1,045.8% in the third quarter. Venturi Wealth Management LLC now owns 5,259 shares of the company’s stock worth $112,000 after purchasing an additional 4,800 shares during the last quarter. 8.37% of the stock is owned by hedge funds and other institutional investors.

About Fresenius Medical Care

(Get Free Report)

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.

See Also

Receive News & Ratings for Fresenius Medical Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care and related companies with MarketBeat.com's FREE daily email newsletter.